Suppr超能文献

慢性血管紧张素转换酶受体阻滞剂预处理对急性心肌梗死患者经皮冠状动脉介入治疗无复流现象的影响。

Effect of chronic pretreatment of angiotensin-converting receptor blocker on no-reflow phenomenon in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

机构信息

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

出版信息

Cardiovasc Ther. 2013 Jun;31(3):e7-e11. doi: 10.1111/j.1755-5922.2012.00314.x.

Abstract

AIMS

Angiotensin receptor blockers (ARBs) exert favorable effects on the vascular system, which are not directly related to hypertension lowering function. The no-reflow phenomenon determines the prognosis in patients after acute myocardial infarction (AMI). Early ARB treatment has many beneficial effects on the prognosis after AMI. In this study, we tested the hypothesis that ARB treatment before admission would have beneficial effects on the development of the no-reflow phenomenon after infarction.

METHODS

We investigated 276 consecutive patients with AMI undergoing successful primary percutaneous coronary intervention (PCI). No-reflow was defined as thrombolysis in myocardial infarction (TIMI) flow grade <3, which was determined by the TIMI frame count method using angiographic images obtained just after PCI and stenting.

RESULTS

Compared with patients without ARB treatment, patients with ARB had more frequently hypertension and ST resolution (P < 0.05), but no significant difference was found in the other clinical characteristics (age, sex, Hyperlipidaemia, Diabetes mellitus, etc) between the two groups. A total of 51 patients receiving chronic ARB treatment before admission have lower incidence of the no-reflow phenomenon than those without chronic ARB treatment (8.7% and 26.7%, P= 0.003). However, the incidence of the no-reflow phenomenon between the patients with and without hypertension had no significant difference. Multivariable logistic regression analysis revealed that ARB pretreatment was a significant predictor of the no-reflow phenomenon, whereas blood pressure was found to be insignificant.

CONCLUSION

Chronic pretreatment of ARB is associated with the reduction of the no-reflow phenomenon in patients with reperfused AMI and could preserve microvascular integrity after AMI independent of blood pressure lowering, which may contribute to better functional recovery.

摘要

目的

血管紧张素受体阻滞剂(ARB)对血管系统具有有利影响,而这些影响与降低血压的功能不直接相关。无再流现象决定了急性心肌梗死(AMI)患者的预后。AMI 后早期 ARB 治疗对预后有许多有益影响。在这项研究中,我们检验了这样一个假设,即在入院前进行 ARB 治疗会对梗塞后无再流现象的发展产生有益影响。

方法

我们调查了 276 例接受成功的直接经皮冠状动脉介入治疗(PCI)的连续 AMI 患者。无再流现象定义为心肌梗死溶栓治疗(TIMI)血流分级 <3,通过 TIMI 帧数计数法,使用 PCI 和支架置入术后即刻获得的血管造影图像来确定。

结果

与未接受 ARB 治疗的患者相比,ARB 治疗组更常伴有高血压和 ST 段缓解(P < 0.05),但两组在其他临床特征(年龄、性别、高脂血症、糖尿病等)方面无显著差异。与未接受慢性 ARB 治疗的患者相比,共 51 例入院前接受慢性 ARB 治疗的患者无再流现象的发生率较低(8.7%和 26.7%,P=0.003)。然而,高血压患者和无高血压患者的无再流现象发生率无显著差异。多变量逻辑回归分析显示,ARB 预处理是无再流现象的显著预测因子,而血压则无显著意义。

结论

在再灌注 AMI 患者中,ARB 的慢性预处理与无再流现象的减少相关,并可在不降低血压的情况下保护 AMI 后微血管的完整性,这可能有助于更好的功能恢复。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验